Forbes, Bloomberg, Global Press Cover Medical Marijuana, Inc. Subsidiary HempMeds® Mexico First Office Opening in Monterrey, Mexico
Coverage Also Highlights Company’s Appointment of Renowned Medical Cannabis Advocate and Por Grace Foundation Founder Raul Elizalde as President
SAN DIEGO, July 6, 2017 /PRNewswire/ — Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that its subsidiary HempMeds® Mexico received international media attention during the July 28, 2017 inauguration of HempMeds® Mexico’s first office in Monterrey, Nuevo Leon, Mexico. Coverage also included the Company’s appointment of medical cannabis activist and Por Grace Foundation founder Raul Elizalde as President in Mexico.
A Huffington Post article, “Monterrey: de ciudad industrial a meca de la marihuana medicinal,” or “Monterrey: from industrial city to medical marijuana mecca,” and other news coverage from major international and national Mexico news outlets discuss the opening of HempMeds® Mexico’s new office in Mexico and recent medical cannabis reforms that are sweeping the country. Mexico President Pena Nieto signed a bill into law June 19, 2017 that officially legalized the cultivation, production, and use of cannabis products with less than 1% THC for medical use in Mexico.
An article from Forbes, “5 retos para la venta de marihuana medicinal en México,” or “5 challenges for the sale of medical marijuana in Mexico,” discusses HempMeds® Mexico’s strategy for cannabidiol (CBD) product development, scientific research, and education in Mexico.
“We appreciate the outpouring of support that we received at the opening of the first HempMeds® Mexico office in Monterrey, Mexico, which reflects a growing demand for the Company’s zero-Tetrahidrocannabidiol (THC) Real Scientific Hemp Oil-X™ (RSHO-X™),” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “The extensive coverage that we received from both local and international media is a testament to the worldwide interest in cannabis reform happening in Mexico, and the efforts of HempMeds® Mexico to provide products for this rapidly expanding CBD hemp oil market.”
Coverage from the event included:
About HempMeds® Mexico
HempMeds®Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.